General
Preferred name
FLUPIRTINE
Synonyms
FLUPIRTINE MALEATE ()
Flupirtin maleate ()
Katadolon maleate ()
Ethyl {2-amino-6-[(4-fluorobenzyl)amino]-3-pyridinyl}carbamate (2Z)-2-butenedioate (1:1) ()
Flupirtine (Maleate) ()
D 9998 (Maleate) ()
D 9998 ()
Flupirtinte maleate ()
W-2964M ()
D-9998 ()
W-2964 ()
Flupirtina ()
Flupirtinte ()
Flupirtine-d4 (hydrochloride) ()
P&D ID
PD009292
CAS
75507-68-5
56995-21-2
56995-20-1
1198579-27-9
1324717-75-0
Tags
available
drug
drug candidate
First approval
1986
Drug indication
Pain
Cancer related pain
Fibromyalgia
Drug Status
approved
investigational
withdrawn
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Flupirtine Maleate is a brain penetrant, and orally bioavailable, non-opioid and centrally acting analgesic agent. Flupirtine Maleate is an indirect N-methyl-D-aspartate receptor (NMDAR) antagonist. Neuroprotective properties[1][2].
PRICE 37
DESCRIPTION Flupirtine(D 9998) is a selective neuronal potassium channel opener that also has NMDA receptor antagonist properties.;IC50 Value: ;Target: Potassium channel; NMDA receptor;in vitro: High concentrations of flupirtine antagonized inward currents to NMDA(200 microM) at -70 mV with an lC50 against steady-state responses of 182.1+/-12.1 microM. The effects of flupirtine were voltage-independent and not associated with receptor desensitization making actions within the NMDA receptor channel or at the glycine modulatory site unlikely. NMDA receptor antagonism probably has little relevance for the clinical efficacy of flupirtine as the concentrations needed were far higher than those achieved in clinical practice. However, the activation of a G-protein-regulated inwardly rectifying K+ channel was identified as an interesting molecular target site of flupirtine. In the next stage, the central nervous spectrum of action of experimental K+ channel openers (PCO) was considered. As far as they have been studied, experimental K+ channel openers display a spectrum of action comparable to that of flupirtine [1]. Therapeutic flupirtine concentrations (¡Ü10 M) did not affect voltage-gated Na(+) or Ca(2+) channels, inward rectifier K(+) channels, nicotinic acetylcholine receptors, glycine or ionotropic glutamate receptors. Flupirtine shifted the gating of K(V)7 K(+) channels to more negative potentials and the gating of GABA(A) receptors to lower GABA concentrations [2]. Cell exposure to flupirtine decreased the amplitude of delayed rectifier K(+) current (I(K(DR))) with a concomitant raise in current inactivation in NSC-34 neuronal cells [4].;in vivo: Rats were trained to discriminate the novel analgesic flupirtine (10.0 mg/kg i.p., 10 min) from no drug under a two-choice fixed-ratio 5 shock-termination schedule. Flupirtine yielded a dose-response curve with an ED50 of 3.87 mg/kg. The opioid analgesics pentazocine, codeine and tramadol failed to produce flupirtine appropriate responding. The opioid antagonist naltrexone did not antagonize the discriminative effects of flupirtine [3]. Both morphine (ED = 0.74 mg/kg) and flupirtine (ED = 3.32 mg/kg) caused dose-related anti-hyperalgesia at doses that did not cause sedation [5]. ;Toxicity: Based on study-end data, hepatotoxicity was detected in 31% of patients receiving flupirtine for ¡Ý 6 weeks [6].
DESCRIPTION Selective 5-HT3 antagonist (Tocris Bioactive Compound Library)
DESCRIPTION NMDA glutamate receptor antagonist; centrally acting analgesic (LOPAC library)
DESCRIPTION Flupirtine maleate (Katadolon maleate), a centrally acting non-opioid analgesia, is the salt form of Flupirtine. It is an NMDA receptor antagonist , and also a specific neuronal potassium channel opener. (TargetMol Bioactive Compound Library)
DESCRIPTION KV7 channel activator (Tocriscreen Plus)
Cell lines
0
Organisms
1
Compound Sets
27
AdooQ Bioactive Compound Library
Axon Medchem Screening Library
Cayman Chemical Bioactives
ChEMBL Approved Drugs
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMatrix
Guide to Pharmacology
JUMP-Target 1 Compound Set
LOPAC library
Mcule NIBR MoA Box Subset
MedChem Express Bioactive Compound Library
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Other bioactive compounds
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
Tocris Bioactive Compound Library
Tocriscreen Plus
Withdrawn 2.0
External IDs
91
Properties
(calculated by RDKit )
Molecular Weight
304.13
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
3
Rotatable Bonds
5
Ring Count
2
Aromatic Ring Count
2
cLogP
2.98
TPSA
89.27
Fraction CSP3
0.2
Chiral centers
0.0
Largest ring
6.0
QED
0.79
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target Type
Ion Channels
Selectivity
NMDA
Pathway
Membrane Transporter/Ion Channel
Neuroscience
Neuronal Signaling
Primary Target
Voltage-gated Potassium (KV) Channels
MOA
Activator
Voltage-Gated K(V) 7 (KCNQ) Channel Activators
glutamate receptor antagonist
Member status
member
Target
ADRA2A, KCNQ1, KCNQ2
Analgesic
KCNQ2
DNA/RNA Synthesis
GABA Receptor
iGluR
Potassium Channel
NMDA Receptor
Indication
pain relief
ATC
N02BG07
Toxicity type
NULL
Source data